Last reviewed · How we verify
Lipoic Acid and Omega-3 Fatty Acids in Alzheimer's Disease
The purpose of this study was to see if taking lipoic acid plus omega-3 fatty acids (omega-3s) can slow the Alzheimer's disease (AD) process. To see if the treatment can slow the AD process, the investigators looked at changes in memory and changes in a person's daily activities over 18 months.
Details
| Lead sponsor | Oregon Health and Science University |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 67 |
| Start date | 2010-09 |
| Completion | 2014-12 |
Conditions
- Alzheimer's Disease
Interventions
- Lipoic acid and fish oil concentrate
- Placebo
Primary outcomes
- Change From Baseline in Activities of Daily Living (ADL) at 18 Months — Baseline and 18 months
The Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) is used to assess activities of daily living in people with AD using a structured interview to ask the AD participant's caregiver/study partner to assess functional ability over a wide range of performance measures. A higher ADL score indicates greater impairment in functional ability; scores range from 0 to 27. - Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 18 Months — Baseline and 18 months
The ADAS-cog assesses general cognitive function over multiple domains and evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates greater impairment on a range of scores from 0 to 70. A total score of 70 indicates maximum severity.
Countries
United States